Protective effect of pentoxifylline plus thalidomide against septic shock in mice

International Journal of Experimental Pathology

Volumn 80, Issue 1, 1999, Pages 11-16

  Arrieta, Oscar ^a   Ortiz Reyes, Araceli ^b   Rembao, Daniel ^b   Calvillo, Minerva ^b   Rivera, Erika ^b   Sotelo, Julio ^b  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b NONE

Author keywords

Histopathology; Pentoxifylline; Septic shock; Thalidomide

Indexed keywords

PENTOXIFYLLINE; THALIDOMIDE;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; HEART; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; LIVER; LUNG; MALE; MOUSE; PRIORITY JOURNAL; SALMONELLA; SEPTIC SHOCK; SMALL INTESTINE;

ANIMALS; DRUG THERAPY, COMBINATION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER; MALE; MICE; MICE, INBRED STRAINS; PENTOXIFYLLINE; PLATELET AGGREGATION INHIBITORS; SHOCK, SEPTIC; SURVIVAL RATE; THALIDOMIDE;

EID: 0032973519     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2613.1999.00085.x     Document Type: Article

References (24)

1. AMBRUS J.L., STADLER S. & KULAYLAT M. (1995) Hemorreologic effects of metabolites of Pentoxifylline. J. Med. 26, 65-75.
2. AMERICAN COLLEGE OF CHEST PHYSICANS/SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE COMMITTEE (1992) Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit. Care Med. 20, 864-874.
3. DANNER R.L. (1991) Endotoxemia in human septic shock. Chest. 99, 169.
4. ERIKSSON T., BJORKMAN S., FYGE A. & EKBERG H. (1992a) Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J. Chromatogr. 582, 211-216.
5. ERIKSSON T., RIESBECK K., OSTRAAT O., EKBERG H. & BJORKMAN S. (1992b) Drug exposure and flow cytometry analyses in a thalidomide schedule that prolongs rat cardiac graft survival. Transplant. Proc. 24, 2560-2561.
6. FRAMPTON J.E. & BROGDEN R.N. (1995) Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of perioheral vascular and cerebrovascular disorders. Drugs Aging 7, 480-503.
7. GLAUSER M.P., HEUMANN D., BAUMGARTHER J.D. & COHEN J. (1994) Pathogenesis and potencial strategies for prevention and treatment of septic shock: an update. Clin. Infect. Dis. 18 (Suppl. 2), S205-S216.
8. HARDAWAT A.M. (1996) Responses of the microcirculation during sepsis/septic shock. Crit. Care. Med. 24, 1072-1077.
9. HOOD S.C., MOHER D. & BARBER G.G. (1996) Management of intermittent claudication with pentoxifylline: meta-analysis of randomized contrlled trials. Can. Med. Assoc. J. 155 (8), 1053-1059.
10. JEWETT A. & BONAVIDA B. (1994) Pentoxifylline suppress interleukin 2 mediated activation of immature human natural killer ceels by inhibiting endogenous tumor necrosis factor alpha secretion. J. Clin. Immunol. 14, 31-38.
11. JILG M., BARSIG J., LEIST M., KUSTERS S., VOLK H.-D. & WENDEL A. (1996) Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methylxantine action in murine models of endotoxic shock. J. Pharmacol. Exp. Ther. 278, 421-431.
12. KOCH H.P. (1994) Thalidomide and congeners as anti-inflammatory agents. In. Progress in Medicine Chemistry, Eds. G.P. Ellis & G.B. West. New York: Elsevier Science Publishers, pp. 166-218.
13. KRAUSZ T. & COHEN J. (1992) Shock. In. Oxford Textbook of Pathology, Principles of Pathology, Vol. 1, 1st edn., Eds. J. McGee, P.G. Isaacson & N. A. Wright., pp. 540-551. Oxford University Press, New York.
14. LEHMANN V., FREUDENBERG M.A. & GALANOS C. (1987) Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J. Exp. Med. 165, 657.
15. LESSLAUER W., TABUCHI H., GENTZ R. ET AL. (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolisaccaide-induced lethaly. Eur. J. Immunol. 21, 2883-2886.
16. MCBRIDE W.T., ARMSTRONG M.A. & MCBRIDE S.J. (1996) Immunomodulation: an important concept in modern anaesthesia. Anaesthesia 51, 465-473.
17. MOHLER K.M., SLEATH P.R., FITZNER J.N. ET AL. (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370, 218-220.
18. NEUNER P., KLOSNER G., SCHAUER E. ET AL. (1994) Pentoxifylline in vivo down regulates of IL-1B, IL-6, IL-8 and tumour necrosis factor a by human peripheral blood mononuclear cells. Immunology 83, 262.
19. OSTROSKY L., SOTO J.L., ANGELES V. ET AL. (1996) Effects of Pentoxifylline or Dexametasone in combination with Amphoterincin B in Experimental Murine Cerebral Cryptoccocosis. Evidence of Neuroexcitatory Pathogenic Mechanisms. Antimicrob. Agent Chemther. 40, 1194.
20. PALENCIA G., ARRIETA O., RIOS C., ALTAGRACIA M., KRAVZOV J. & SOTELO J. (1998) Effect of thalidomide against different tumors in rodents. J. Exp. Therap. Oncol. in press.
21. RANDALL T. (1990) Thalidomide's back in the News, but in more favorable circumstances. J.A.M.A. 263, 1467-1468.
22. SAEZ-LLORENS X., RAMILO M., MUSTAFA J. ET AL. (1994) Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis. Antimicrob. Agents Chemother. 34, 837-843.
23. SCHMIDT H., RUSH B., SIMONNIAN G., MURPHY T., HSIEH J. & CONDON M. (1996) Thalidomide inhibits TNF response and increases survival following endotoxin inyection in rats. J. Surg. Res. 63, 143-146.
24. VADAS P. & PRUZANSKI W. (1993) Induction of group II phospholipasa A2 expression and pathogenesis of the sepsis syndrome. Circulatory Shock 33, 160-167.